The acquisition will grant Profusa exclusive rights to the PanOmics platform, enhancing its biosensing and diagnostics capabilities.
BioInsights will provide sample access for validation and receive a 3 percent royalty on net revenue. Additionally, BioInsights can nominate an independent Board member to replace an outgoing member.
Profusa plans to seek further financing to support the development and scaling of its new capabilities. The integration of PanOmics with Profusa’s existing technologies aims to create multi-indication diagnostic assays, real-time physiological monitoring solutions, and data-driven clinical decision tools.
This strategic move is expected to enable Profusa to enter multiple high-growth markets and establish a scalable, recurring-revenue diagnostics and monitoring platform.
Dr. Ben Hwang, Profusa Chairman and CEO, stated, “This is a pivotal step in the evolution of Profusa. The combination of the PanOmics platform and our collaboration with Mayo Clinic positions us to build a differentiated, scalable presence in precision diagnostics and surgical monitoring.”
In pre-market trading, Profusa’s stock surged 144.74 percent to $1.86, up $1.10 from the previous close of $0.58, within a 52-week range of $0.41 to $412.50.
 plans to acquire the PanOmics diagnostics platform from BioInsights for $30 million in equity, expanding its diagnostics capabilities.){kind=link}